Gain Therapeutics (NASDAQ:GANX) Stock Rating Reaffirmed by HC Wainwright

Gain Therapeutics (NASDAQ:GANXGet Free Report)‘s stock had its “buy” rating reissued by HC Wainwright in a note issued to investors on Monday, Benzinga reports. They presently have a $9.00 price target on the stock. HC Wainwright’s price objective points to a potential upside of 138.73% from the stock’s current price.

Separately, Chardan Capital reissued a “buy” rating and issued a $6.00 target price on shares of Gain Therapeutics in a research report on Wednesday, March 27th.

Check Out Our Latest Stock Report on GANX

Gain Therapeutics Stock Up 1.1 %

Shares of NASDAQ GANX opened at $3.77 on Monday. The firm has a market cap of $61.15 million, a price-to-earnings ratio of -2.20 and a beta of 0.43. The company has a quick ratio of 3.59, a current ratio of 3.59 and a debt-to-equity ratio of 0.04. Gain Therapeutics has a 52-week low of $2.00 and a 52-week high of $6.19. The business’s 50 day moving average is $4.31 and its two-hundred day moving average is $3.44.

Hedge Funds Weigh In On Gain Therapeutics

Several institutional investors have recently modified their holdings of the business. Geode Capital Management LLC grew its stake in shares of Gain Therapeutics by 4.5% during the first quarter. Geode Capital Management LLC now owns 94,207 shares of the company’s stock worth $454,000 after purchasing an additional 4,093 shares in the last quarter. BlackRock Inc. boosted its stake in Gain Therapeutics by 17.1% in the second quarter. BlackRock Inc. now owns 29,024 shares of the company’s stock valued at $130,000 after acquiring an additional 4,246 shares in the last quarter. Renaissance Technologies LLC boosted its stake in Gain Therapeutics by 16.6% in the first quarter. Renaissance Technologies LLC now owns 38,700 shares of the company’s stock valued at $187,000 after acquiring an additional 5,500 shares in the last quarter. Vanguard Group Inc. boosted its stake in Gain Therapeutics by 9.6% in the third quarter. Vanguard Group Inc. now owns 70,280 shares of the company’s stock valued at $231,000 after acquiring an additional 6,162 shares in the last quarter. Finally, Dimensional Fund Advisors LP boosted its stake in Gain Therapeutics by 55.8% in the first quarter. Dimensional Fund Advisors LP now owns 18,607 shares of the company’s stock valued at $90,000 after acquiring an additional 6,661 shares in the last quarter. Institutional investors and hedge funds own 11.97% of the company’s stock.

Gain Therapeutics Company Profile

(Get Free Report)

Gain Therapeutics, Inc, a biotechnology company, researches and develops novel therapies to treat diseases caused by protein misfolding in Switzerland and Spain. It focuses on rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover allosteric sites on misfolded proteins and identify proprietary small molecules that bind these sites, restore protein folding, and treat disease.

See Also

Receive News & Ratings for Gain Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gain Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.